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Introduction 13 
Pulmonary nodules are detected with increasing frequency due to widespread 14 
use of computed tomography (CT).1,2 The prevalence of incidental pulmonary 15 
nodules on standard CT studies is around 13%, while lung cancer screening 16 
will detect lung nodules in up to 53% of subjects, leading to a lung cancer 17 
prevalence of around 1.4% (0.5–2.7%).3 The optimal diagnostic approach for 18 
the management of indeterminate pulmonary nodules has been the subject of 19 
much discussion.4  20 
 21 
The widely accepted guidelines published by the British Thoracic Society 22 
(BTS) and the Fleischner Society recommend the minimum nodule diameter 23 
 2 
thresholds and CT follow-up time intervals for surveillance of solitary nodules 24 
smaller than 8 mm.3,5 For nodules of >8 mm (300 mm3), the BTS guidelines 25 
recommend risk assessment using the Brock model. The above guidelines 26 
recommend either 3-month CT follow-up, work-up with positron emission 27 
tomography (PET) with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG), 28 
tissue sampling, or resection for nodules of >8mm. CT characterisation using 29 
only morphological features is imprecise,6,7 leading to an increased interest in 30 
computer-based radiomics assessment.8–15 Serial CT imaging to monitor 31 
nodule size can be problematic as nodule growth varies with different cancers 32 
and causes patient anxiety.16–18 18F-FDG PET has high sensitivity but lower 33 
specificity of 82% for detecting malignant pulmonary nodules, particularly in 34 
those smaller than 10 mm.19 Imaging guided sampling of small nodules is also 35 
difficult, is associated with complications, and its diagnostic yield decreases 36 
further as nodule size decreases.3,20,21  37 
 38 
Neovascularisation is a complex process known to be central to 39 
carcinogenesis.22 Advances in the imaging technology in the last two decades 40 
have enabled the study of perfusion characteristics within pulmonary 41 
nodules.23–27 As benign and malignant lesions have different vascularity, 42 
different perfusion parameters and dynamic 18F-FDG uptake properties can 43 
be expected.27–32 44 
 45 
The purpose of this pilot study was to evaluate the feasibility and accuracy of 46 
CT perfusion and dynamic 18F-FDG PET imaging in differentiating proven 47 
benign and malignant pulmonary nodules.  48 
 3 
Materials and methods 49 
This single-centre prospective study was approved by the local Research 50 
Ethics Committee (13/SS/0153) and written informed consent was obtained 51 
from all participants.  52 
 53 
Between December 2014 and December 2015, 20 consecutive patients who 54 
were referred to our respiratory outpatient clinic for an indeterminate 55 
incidental pulmonary nodule were recruited. The inclusion criteria were: a) 56 
incidentally detected soft tissue (solid) pulmonary nodules measuring >8 mm 57 
and <30 mm on CT, b) either surgical excision, imaging guided biopsy or 58 
imaging follow up of the nodule planned. The exclusion criteria were: a) 59 
abnormal renal function, b) previous adverse reaction to iodinated contrast 60 
agent, c) known history of malignancy, d) pregnancy or breast feeding, e) 61 
patients who refused or were unable to provide informed consent. 62 
 63 
The patients underwent a dynamic 18F-FDG PET/CT and dynamic perfusion 64 
CT imaging within a 3 week time frame (mean, 6.4 days: range 1–18 days). 65 
Due to technical reasons, the dynamic PET data could not be used in 4 66 
patients for the analysis, one of these patients had two synchronous nodules. 67 
CT perfusion analysis was performed in 17 of the nodules. One patient 68 
declined the CT perfusion scan and 3 patients had significant breathing 69 
artefact on the scans, rendering analysis non-feasible. All nodules were 70 
classified into either benign or malignant on the basis of a histopathological 71 
diagnosis (n=16), or stability during 2 years follow up CT imaging (n=5). 72 
 73 
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Dynamic PET/CT image acquisition: 74 
All patients were fasted for at least six hours before the imaging. Following a 75 
low dose CT scan for attenuation correction and localisation (120 kV, 50 mAs, 76 
5/3 mm), patients were administered 400 MBq of 18F-FDG intravenously, and 77 
a dynamic 60 minute image acquisition was performed using a Siemens 78 
Biograph PET/CT scanner (Siemens Healthcare, Erlangen, Germany). 79 
Respiratory-gated PET data were reconstructed using a 15-frame protocol (7 80 
frames×180 s, 7×300 s, 1×240 s), a matrix size of 256×256×53 with a voxel 81 
size of 2.65×2.65×3.00 mm3, and subsets expectation maximization (OSEM) 82 
method. A conventional PET/CT scan was performed on completion of the 83 
dynamic phase of the scan at 1 hour after injection of the tracer. 84 
 85 
Perfusion volume CT acquisition: 86 
Dynamic perfusion CT scans were performed as previously described 25,28,33,34 87 
on a 320-detector row CT scanner (Aquilion ONE; Toshiba Medical Systems, 88 
Tokyo, Japan) with 16 cm field of view coverage. Imaging was performed at 0, 89 
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 30, 40, 50, 60, 90, 120 seconds, 3 90 
minutes, 4 minutes, and 10 minutes following the intravenous injection of 70 91 
ml of iodinated contrast (Iomeron 400 mg/ml, Bracco, Milan, Italy) followed by 92 
a 30 ml bolus of saline both at 9 ml/s through a 16 G cannula sited in the ante 93 
cubital fossa. Acquisition parameters were 100 kV, 100 mA, 0.5 seconds 94 
rotation time, 320 x 0.5 mm collimation, 512 x 512 matrix. 95 
 96 
Image Analysis: 97 
Dynamic PET/CT: 98 
 5 
Reconstructed images were imported into PMOD 3.409 software (PMOD 99 
Technologies, Zurich, Switzerland) and the input function was determined by 100 
placing a spherical volume of interest (VOI) with diameter of 1 cm in the 101 
ascending aorta. VOIs were drawn around the pulmonary nodules semi-102 
automatically with a threshold of 50% of the maximum voxel value within the 103 
nodule, and then the VOIs were copied to the dynamic imaging sequence to 104 
obtain the time activity curves (TACs) (Figure 1). The influx constant Ki (min
-1 105 
or (ml plasma)*(ml tissue)-1*min-1)) was determined by Patlak analysis.35 The 106 
Patlak plot model is a graphical analysis technique based on a 2-tissue 107 
compartment model with irreversibly trapped tracer. A mathematical 108 
transformation of the tissue compartment and plasma TACs produces a 109 
straight line plot which provides information about the blood volume (BV) of 110 
the tissue compartment and the exchange rate (Ki) (Figure 2).  111 
 112 
Conventional PET/CT scan: 113 
The maximum standardised uptake value (SUVmax) was measured for each 114 
nodule on conventional FDG PET/CT images. For the semi-quantitative 115 
analysis, the mean standardised uptake values (SUVmean) were measured of 116 
the ascending aorta at the level of the arch, and within the right lobe of the 117 
liver. SUV ratios (SUR) were calculated between the nodule SUVmax, and the 118 
SUVmean of the mediastinal blood pool (SURBLOOD) and liver 119 
(SURLIVER). Criteria for malignancy were specified as SUVmax ≥2.5; SURBLOOD 120 
≥1.56; SURLIVER ≥1.12. Qualitative assessment PET features were specified 121 
as following: 0 = no visible uptake; 1 = uptake less than mediastinal blood 122 
pool; 2 = uptake comparable to mediastinal blood pool; 3 = uptake greater 123 
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than mediastinal blood pool; 4 = distant metastases. Qualitative specified 124 
criteria for malignancy was PET grade ≥ 3.36,37 Volumes of interest (VOIs) 125 
were placed over the nodules, the ascending aorta at the level of the arch, 126 
and within the right lobe of the liver for determination of the SUVmean and 127 
SUVmax values using OsiriX software (OsiriX, version 8.0.1 64 bit; OsiriX 128 
Imaging Software, Geneva, Switzerland). 129 
 130 
Perfusion CT: 131 
Perfusion analysis was performed using Body Perfusion Application on a 132 
Vitrea Workstation (Vitrea fX 6.0; Vital Images, Minnetonka, MN, USA). 133 
Regions of interest (ROIs) were placed over the pulmonary nodules and 134 
contralateral lung parenchyma (diameter range, 7–29 mm) on all perfusion CT 135 
images. Arterial input was determined by placing 1 cm ROI over the main 136 
pulmonary artery. Time-density graphs were then reviewed and adjustments 137 
to start point and end point of the maximum slope were made if needed to 138 
define the optimal slope range. Arterial flow perfusion maps overlaying CT 139 
images were visually analysed and ROIs were placed over the nodules to 140 
obtain the equivalent blood volume parameter calculated by Patlak plot model 141 
(BV, expressed in ml per 100 ml) and Arterial Flow (AF, expressed in ml per 142 
100g per minute) using single-input maximum slope model for calculation. 143 
 144 
Statistical Analysis: 145 
All results were expressed as mean ± standard deviation (SD) unless 146 
indicated. Ki and perfusion indices BV and AF of benign and malignant 147 
nodules were statistically compared using the nonparametric Mann-Whitney U 148 
 7 
test. The accuracy of the different techniques and parameters was tested with 149 
area under the curve (AUC) in receiver operating characteristic (ROC) 150 
analysis with 95% confidence interval (CI). Comparison between the ROCs 151 
was performed using DeLongs test. Youdin index analysis was used to derive 152 
the optimised cut-point values. Mann-Whitney U test and ROC curve analyses 153 
were performed on GraphPad Prism version 8.2.1 for Windows (GraphPad 154 
Software, San Diego, CA, USA). Youdin index analysis and nonparametric 155 
DeLongs test were performed on MedCalc Statistical Software version 19.8 156 
(MedCalc Software Ltd, Ostend, Belgium; https://www.medcalc.org; 2021). A 157 
p value < 0.05 was considered statistically significant.  158 
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Results  159 
The demographic data, average nodule size, SUVmax, metabolic parameter 160 
relating to the pulmonary nodules through dynamic 18F-FDG PET/CT, and 161 
perfusion parameters through perfusion CT for the benign and malignant 162 
nodules are summarised in Table 1 and Fig 3. We analysed 21 soft tissue 163 
nodules in 20 patients (male/female=11/9; mean age±SD: 65.3±7.4; age 164 
range: 50–76 years) with mean nodule diameter±SD of 20.1±7.5 mm (9–29 165 
mm); mean nodule volume±SD: 2849±2338.7 mm3 (247–9348 mm3). 52% of 166 
the nodules were located in the upper lung lobes (right upper lobe 7/21, left 167 
upper lobe 4/21), 48% were in middle and lower lung lobes (right middle lobe 168 
2/21, right lower lobe 6/21 and left lower lobe 2/21). Final diagnosis was 169 
determined after surgical resection in 10 patients, core CT guided biopsy or 170 
bronchoscopy in 6 patients, and over 2 years stability on follow up CT imaging 171 
in 5 patients. 172 
As shown in Table 1 and Fig 3, SUVmax derived from the conventional 
18F-173 
FDG PET/CT and Ki derived from dynamic 
18F-FDG PET/CT were 174 
significantly higher in malignant nodules than in benign nodules. Also, the 175 
Patlak model derived BV on perfusion CT was significantly higher in malignant 176 
nodules. The difference in AF between the benign nodules and malignant 177 
nodules was not statistically significant.  178 
The benign outlier on 18F-FDG PET/CT (SUVmax=6.3) and dynamic 
18F-FDG 179 
PET/CT (Ki=0.0179 min
-1) was an 18 mm nodule of inflammation and fibrosis 180 
(Fig 3 (a) and (b)). The perfusion CT indices BV and AF in this nodule were 181 
relatively low, 3.8 ml/100ml and 51.5 ml/100g/min, respectively (Fig 3 (c) and 182 
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(d)). The two malignant outliers on conventional 18F-FDG PET/CT and 183 
dynamic 18F-FDG PET/CT were 12 mm and 16 mm mucinous 184 
adenocarcinomas in situ (12 mm nodule with SUVmax=0.7 and Ki=0.0015 min
-1 
185 
(BV and AF analysis non-feasible due to respiratory motion artefact); 16 mm 186 
nodule with SUVmax=1.0, Ki=0.0033 min
-1, BV=48.8 ml/100ml and AF=154.1 187 
ml/100g/min) (Fig 3 (a) and (b)). The mean CT densities of these two nodules 188 
on unenhanced CT images were 16.3HU and 15.9HU, while the mean density 189 
± SD of all benign and malignant nodules analysed was 24.55±12.01 HU. The 190 
benign outlier in AF on perfusion CT was a 10 mm perivascular epithelioid cell 191 
tumour (PEComa), AF=272.7 ml/100g/min (Fig 3 (d)). The BV in this nodule 192 
was 20.5 ml/100ml, the 18F-FDG PET/CT indices were low, SUVmax=0.7 and 193 
the Ki=0.001 min
-1. 194 
Table 2 and Figure 4(a) show diagnostic accuracy of conventional PET/CT 195 
derived parameters with pre-specified and derived cut-point values though 196 
ROC analysis.36,37 SURBLOOD parameter had overall highest accuracy, 197 
however, pairwise comparison of AUCs showed no significant difference (p = 198 
0.5308 vs SUVmax; p = 1.0000 vs SURLIVER;  p =0.1083 vs PET grade). ROC 199 
analysis and diagnostic accuracy for the diagnosis of malignancy by dynamic 200 
18F-FDG PET/CT parameter Ki, and perfusion CT indices BV and AF 201 
compared to SURBLOOD are further detailed in Table 2 and Figure 4(b). 202 
Pairwise comparison of AUCs of SURBLOOD, Ki, BV and AF  showed no 203 
significant difference in their diagnostic performances (p > 0.1 for all 204 
comparisons). 205 
  206 
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Discussion 207 
Our results demonstrate that the metabolic parameter Ki of dynamic 
18F-FDG 208 
PET/CT and the BV parameter of perfusion CT are significantly lower in 209 
benign nodules. 210 
Our study showed that the diagnostic accuracy of the conventional 18F-FDG 211 
PET/CT was best when semi-quantitative assessment and measuring the 212 
uptake ratio of the lung nodule to the mediastinal blood pool with cut-point 213 
criteria for malignancy SURBLOOD ≥1.56 was used. This has been confirmed in 214 
a larger multicenter trial by Evangelista et al.36 Different to the SPUTNIK trial 215 
which has shown SUVmax to be the most accurate and reproducible technique 216 
with a caveat of  introducing additional cut-point values altered according to 217 
the nodule size, we did not see significant improvement in diagnostic 218 
accuracy when replicating the multiple cut-points in our group of nodules (see 219 
* in Table 2).37  220 
The accuracies of the new metabolic parameter Ki and perfusion parameter 221 
BV were not significantly different to the conventional 18F-FDG PET/CT. The 222 
derived Ki cut-point for malignancy was ≥0.01 min-1 resulting in 223 
sensitivity/specificity/accuracy of 77.8%/85.7%/81.3%, respectively. This is in 224 
good agreement with Ki cut-point ≥0.014 min-1 reported in the study by Huang 225 
et al. (n=35).26 The derived BV cut-point value of ≥21 ml/100ml for malignancy 226 
showed comparable diagnostic accuracy to conventional and dynamic 18F-227 
FDG PET/CT parameters. The high specificity of BV demonstrated in our 228 
nodules would need to be confirmed in larger studies.  229 
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The benign outlier on dynamic 18F-FDG PET/CT with a high Ki parameter 230 
histopathologically represented inflammation (Fig 3 (b)). Higher metabolic 231 
activity is not only a feature of malignant cells, it can be observed in 232 
inflammatory nodules due to increased glucose metabolism in granulocytes 233 
and macrophages in a range of diseases, including fungal and necrobiotic 234 
rheumatoid nodules, sarcoidosis, tuberculosis, and other granulomas.38,39 235 
Dual time PET/CT did not prove to be useful for differentiating benign and 236 
malignant pulmonary nodules with an SUVmax less than 2.5 in regions with 237 
high prevalence of granulomatous disease.40,41 Huang et al. showed that 238 
dynamic 18F-FDG PET/CT is valuable in differentiating benign from malignant 239 
pulmonary nodules with the potential to differentiate malignant from 240 
granulomatous disease.26 Our study showed limited diagnostic accuracy of 241 
the dynamic 18F-FDG PET/CT in assessing inflammatory nodules. 242 
The malignant outliers on dynamic 18F-FDG PET/CT with low Ki parameters 243 
were histopathologically mucinous adenocarcinoma in situ. Other malignant 244 
nodules in which low metabolic activity can be measured on 18F-FDG PET/CT 245 
are minimally invasive adenocarcinoma, carcinoid, and lung lymphoma.38,42 246 
Another important finding was that both malignant nodules with low metabolic 247 
activity were of lower CT density analysed on the initial perfusion CT images 248 
but also appreciable on low-dose CT scan of PET/CT examination. Further 249 
studies on low density lung nodules are needed for evaluation of using lower 250 
cut-point values for malignancy in conventional and dynamic PET/CT. 251 
Malignant lung nodules with low CT density and measuring less than 1 cm are 252 
known to have low metabolic activity on conventional 18F-FDG PET/CT.43,44 253 
Berger et al. have reported up to 41% of lung lesions to be false-negative on 254 
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conventional 18F-FDG PET/CT in analysis of 25 mucinous, hypocellular lung 255 
lesions (3/9 false negative lesions were ≤ 2 cm, range, 1–5 cm).45 Our study 256 
showed a limited diagnostic accuracy of the dynamic 18F-FDG PET/CT in 257 
assessing low density malignant pulmonary nodules with Ki cut-point set at 258 
0.01 min-1.  259 
Dynamic enhancement CT studies help identify false positive results in both 260 
inflammatory and infective conditions, and sometimes in benign vascular 261 
tumours.46,47 The perfusion CT parameters for the inflammatory nodule in our 262 
study were low and indicative of a benign lesion despite high metabolic 263 
activity on 18F-FDG PET/CT. We have shown that the parameters of perfusion 264 
CT of both malignant nodules with low metabolic activity were higher than the 265 
BV and AF in benign nodules. Therefore, our findings indicate parameters of 266 
perfusion CT may aid in the identification of benign nodules with high glucose 267 
metabolic activity and in the identification of malignant nodules with low 268 
glucose metabolic activity. Ohno et al. have shown that perfusion CT is more 269 
specific and accurate than conventional 18F-FDG PET/CT.24,29 Our study on a 270 
small sample of cases suggests that perfusion CT also performs better than 271 
dynamic 18F-FDG PET/CT. 272 
The AF parameter of the perfusion CT obtained by the maximum slope 273 
method was not significantly different between benign and malignant nodules. 274 
Benign nodules had a lower AF parameter value than malignant nodules 275 
overall with one significant benign outlier with markedly high AF. 276 
Histopathologically, this represented an extremely rare ‘light cell’ or ‘sugar 277 
type’ PEComa. There are only about 50 cases of this neoplasm described in 278 
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the literature.48,49 PEComas are more commonly found as angiomyolipomas 279 
in the kidneys, or as lesions in the retroperitoneal space, gastrointestinal tract, 280 
or uterus. Only 7 cases of malignant pulmonary PEComa have been reported 281 
50. A case report of a benign pulmonary PEComa showing early wash-in 282 
enhancement with an early washout pattern of a malignant lesion on perfusion 283 
CT has been reported by Kim et al.51 Despite a markedly high AF, the 284 
PEComa had a BV just under the cut-point value for malignancy and a low 285 
metabolic parameter Ki of dynamic 
18F-FDG PET/CT. The BV parameter in 286 
combination with low Ki parameter proved to be more reliable for defining this 287 
extremely rare histological type of a pulmonary nodule.  288 
Our study has limitations. This pilot study was performed in a small sample of 289 
patients and appropriately powered studies will be required for further 290 
validation. The mean nodule size was 18 mm for benign and 22 mm for 291 
malignant nodules, which would not normally be referred for imaging follow-292 
up. The BTS and Fleischner Society recommended lower thresholds for 293 
nodule follow up (5mm and 6mm, respectively). More novel reconstruction 294 
methods in PET/CT such as specific point spread function (PSF) are enabling 295 
better spatial resolution and enable its use in 6 mm pulmonary nodules.52  296 
Perfusion CT is quite demanding on patients with a prolonged breath-hold, 297 
which limits the availability of reliable data in some patients. All 3 nodules in 298 
which analysis was non-feasible due to the significant breathing artefact were 299 
near the diaphragm (2 in the right lower lobe and 1 in the right middle lobe). 300 
Segmentation of the pulmonary nodules on image analysis is restricted when 301 
the images were affected by respiratory motion artefact, especially in small 302 
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nodules which were also abutting the chest wall or mediastinal structures. 303 
Some authors recommend quiet breathing during the perfusion CT scans but 304 
this is only acceptable in larger lung masses.53 There is a need for further 305 
optimisation of nodule segmentation and advanced image registration 306 
techniques that allow accurate assessment of pulmonary nodules without 307 
need for long breath-hold.23,54 The effective radiation dose for dynamic 18F-308 
FDG PET/CT was around 8 mSv and for perfusion CT around 20 mSv. The 309 
radiation dose for perfusion CT can be improved by reducing the field of view 310 
from 16 cm to the nodule only and reducing tube voltage in smaller size 311 
patients.55  312 
Potential increase in the demand for these not widely available novel dynamic 313 
imaging studies would consequently put additional strain on the imaging 314 
departments with increased demand for scanner time, funding and training of 315 
the staff. Limited capacity for a wider use of the dynamic imaging in lung 316 
nodules could be overcome by developing systems of identification of nodules 317 
with highest diagnostic benefit from dynamic imaging. A multicentre 318 
prospective cohort observational study initiated in 2016 is set to assess the 319 
performance and the cost-effectiveness of the dynamic CT and PET/CT in the 320 
characterisation of solitary pulmonary nodules.56 321 
The small sample size limits the assessments of accuracy in our study. 322 
However, on this small sample we showed increase diagnostic improvement 323 
in the accuracy of diagnosis in both dynamic studies when compared to the 324 
conventional 18F-FDG PET/CT. Specificity in Ki and BV on our small sample 325 
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size were higher at the estimated threshold values of 0.01 min-1 and 21 326 
ml/100ml, respectively. This would need to be confirmed in larger studies. 327 
Early identification of a lung nodule as benign or malignant by analysing its 328 
metabolic and perfusion parameters could reduce the need for CT to monitor 329 
lung nodule size, thereby reducing the number of CT scans required. It could 330 
also reduce the need for CT guided biopsy or other invasive procedures. 331 
Patients with malignant lung nodules could thus be identified more quickly and 332 
referred for radical treatment. With our study, we have demonstrated the 333 
potential of perfusion CT. The BV parameter assessed by perfusion CT was 334 
not only significantly lower in benign nodules, it also aided in correctly 335 
characterising the metabolically active inflammation, hypervascular benign 336 
PEComa and low density malignancy. 337 
In conclusion, this study demonstrated the feasibility of dynamic 18F-FDG 338 
PET/CT and CT perfusion studies in differentiating benign and malignant 339 
pulmonary nodules. The dynamic 18F-FDG PET/CT and perfusion CT derived 340 
blood volume can assist to differentiate benign and malignant lung nodules 341 
and in indeterminate cases, a combined approach can be helpful.   342 
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TABLE 1. The demographic data, average nodule size, SUVmax, metabolic parameter 
relating to the pulmonary nodules through dynamic 18F-FDG PET/CT, and perfusion 
parameters through perfusion CT for the benign and malignant nodules. 
 Benign Nodules Malignant Nodules p value 
Total Number of nodules 9 12  
Number of male patients (%) 5/9 (55 %) 6/12 (50 %)  
Average patient age (years ± SD) 63±7.5 68±6.7  
Average nodule size, Range (mm) 18, 9–29 22, 12–30  
Average SUVmax 18F-FDG PET/CT ± SD 2.2±1.7 7.0±4.5 0.0148 
Number of nodules analysed for 
dynamic 18F-FDG PET/CT 
7 9  
Average Ki ± SD (min-1) 0.0057±0.0071 0.0230±0.0155 0.0311 
Number of nodules analysed for 
perfusion CT parameters 
7 10  
Average BV ± SD (Patlak, ml/100ml) 11.6857±6.7347 28.3400±15.9672 0.0250 







TABLE 2. Comparison of the diagnostic accuracy of different techniques and 
parameters with pre-specified and derived cut-point values for malignancy. 
Parameter Cut-point value/grade Sensitivity (95% CI) Specificity (95% CI) Accuracy 
SUVmax 
Pre-specified ≥2.5* 75.0% (46.8 to 91.1%) 66.7% (35.4 to 87.9%) 71.4% 
Derived ≥3.4 75.0% (46.8 to 91.1%) 88.9% (56.5 to 99.43%) 81.0% 
SURBLOOD 
Pre-specified 
≥1.56 83.3% (55.2 to 97.0%) 88.9% (56.5 to 99.4%) 85.7% 
Derived 
SURLIVER 
Pre-specified ≥1.12 83.3% (55.2 to 97.0%) 66.7% (35.4 to 87.9%) 76.2% 





≥3 66.7% (39.0 to 86.2%) 77.8% (45.3 to 96.0%) 71.4% 
Ki Derived ≥0.01 min-1 77.8% (45.2 to 96.0%) 85.7% (48.7 to 99.3%) 81.3% 
BV Derived ≥21 ml/100ml 70% (39.7 to 89.2%) 100% (64.6 to 100%) 82.4% 
AF Derived ≥65 ml/100g/min 70% (39.7 to 89.2%) 85.7% (48.7 to 99.3%) 76.5% 
 
* adding cut-points SUVmax ≥1.75 and ≥3.6 for nodules <12 mm and >16 mm, respectvely,37 resulted in 
sensitiv ity, specificity and accuracy of 72.7%, 70.0% and 71.4%, respectively. 
 
